View Financial HealthLee's Pharmaceutical Holdings 배당 및 자사주 매입배당 기준 점검 3/6Lee's Pharmaceutical Holdings 수익으로 충분히 충당되는 현재 수익률 3.18% 보유한 배당금 지급 회사입니다.핵심 정보3.2%배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률3.2%배당 성장률-13.3%다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향28%최근 배당 및 자사주 매입 업데이트공시 • Mar 26Lee's Pharmaceutical Holdings Limited Proposes Ordinary Final Dividend for the Year Ended 31 December 2023, Payable on 17 June 2024Lee's Pharmaceutical Holdings Limited proposed ordinary final dividend of HKD 0.01 per share for the year ended 31 December 2023. Date of shareholders' approval is 22 May 2024. Ex-dividend date is 28 May 2024. Record date is 31 May 2024. Payment date is 17 June 2024.공시 • Aug 31Lee's Pharmaceutical Holdings Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, Payable on 04 October 2023Lee's Pharmaceutical Holdings Limited announced interim dividend of HKD 0.008 per share for the six months ended June 30, 2023. Ex-dividend date is 12 September 2023. Record date is 15 September 2023. Payment date is 04 October 2023.모든 업데이트 보기Recent updates공시 • Mar 30Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 21, 2026Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 21, 2026.공시 • Mar 17Lee's Pharmaceutical Holdings Limited to Report Fiscal Year 2025 Results on Mar 30, 2026Lee's Pharmaceutical Holdings Limited announced that they will report fiscal year 2025 results on Mar 30, 2026공시 • Dec 10Lee's Pharmaceutical Holdings Limited (SEHK:950) signed asset purchase agreement to acquire Assets relating to Alexza Business of Alexza Pharmaceuticals, Inc., for $15 million.Lee's Pharmaceutical Holdings Limited (SEHK:950) signed asset purchase agreement to acquire Assets relating to Alexza Business of Alexza Pharmaceuticals, Inc., for $15 million on December 8, 2025. A cash consideration of $10 million will be paid by Lee's Pharmaceutical Holdings Limited. Lee's Pharmaceutical Holdings Limited will pay an earnout/contingent payment of $5 million cash which will be paid on June 1, 2026.. As part of consideration, $15 million is paid towards assets of Assets relating to Alexza Business of Alexza Pharmaceuticals, Inc.,. Assets relating to Alexza Business of Alexza Pharmaceuticals, Inc., reported total common equity of $58.67 million as on December 31, 2024. The expected completion of the transaction is December 8, 2025 to January 21, 2026.공시 • Aug 15Lee's Pharmaceutical Holdings Limited to Report First Half, 2025 Results on Aug 26, 2025Lee's Pharmaceutical Holdings Limited announced that they will report first half, 2025 results on Aug 26, 2025공시 • Mar 27Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 22, 2025Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 22, 2025.공시 • Mar 12Lee's Pharmaceutical Holdings Limited to Report Fiscal Year 2024 Results on Mar 27, 2025Lee's Pharmaceutical Holdings Limited announced that they will report fiscal year 2024 results on Mar 27, 2025공시 • Aug 16Lee's Pharmaceutical Holdings Limited to Report First Half, 2024 Results on Aug 28, 2024Lee's Pharmaceutical Holdings Limited announced that they will report first half, 2024 results on Aug 28, 2024공시 • Aug 02Lee's Pharmaceutical Holdings Limited Announces the First Patient Has Been Enrolled in A Phase I Clinical Trial to Receive Au409 At Queen Mary Hospital, Hong KongLee's Pharmaceutical Holdings Limited announced that on 15 July 2024, the first patient has been enrolled in a Phase I clinical trial to receive AU409 at Queen Mary Hospital, Hong Kong. This trial focuses on patients with advanced hepatocellular carcinoma who have previously failed standard first-line treatment. AU409 is a novel drug discovered and owned by Auransa Inc. ("A Phase I, Single-arm, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of AU409 Capsule in Advanced Hepatocellular Carcinoma Patients who failed Standard Treatment" is led by Principal Investigator Dr. Chi Leung Chiang, MD. The primary objectives are to determine the maximum tolerated dose and recommended Phase II dose, as well as to characterise the safety and tolerability of AU409. Secondary objectives include assessing the pharmacokinetics and preliminary anti-tumor activity of AU409. AU409 is a novel drug discovered and owned by Auransa Inc. ("Auransa"), and is manufactured by Zhaoke Pharmaceutical (Guangzhou) Limited, a wholly owned subsidiary of the Group, in compliance with the Good Manufacturing Practice regulations set by the U.S. Food and Drug Administration. This Phase I clinical trial marks the first-in-human study in Asia and is expected to conclude by the second quarter of 2025. The results of this study will be used for China's new drug registration purpose.공시 • Jul 02Lee's Pharmaceutical Holdings Limited Appoints Huang Zuie Chin as A Non-Executive DirectorThe board of directors of Lee's Pharmaceutical Holdings Limited announced that after considering the recommendation of the nomination committee of the Company, the Board has appointed Mr. Huang Zuie Chin as a non-executive Director with effect from 2 July 2024. Mr. Huang, aged 59, has over 35 years' experience in the life science and investment industry together with 20 years' experience in the pharmaceutical and biotech industry holding senior roles in business development, sales, marketing and research and development. In 2011, he joined Kleiner Perkins Caufield & Byers China as a managing partner and focuses on the firm's life science practice. He is also the founding managing partner of Panacea Healthcare Venture Capital, including Panacea Venture Healthcare Fund I, L.P., Panacea Venture Healthcare Fund II, L.P. and Panacea Opportunity Fund I, L.P., which are venture capitals focusing on investments in innovative and transformative early and growth stage healthcare and life sciences companies worldwide. Mr. Huang received a Master of Business Administration (MBA) from the Stanford Graduate School of Business and a Bachelor of Science degree in chemical engineering from the University of California, Berkeley. He is a non-executive director of Kindstar Globalgene Technology Inc., whose shares are listed on The Stock Exchange of Hong Kong Limited (the "Stock Exchange") (Stock Code: 9960) since 2012, and a director of Connect Biopharma Holdings Limited, a company whose shares are listed on Nasdaq Global Market since 2024. Between 2020 and 2023, he was an executive director of Auto Italia Holdings Limited, whose shares are listed on the Stock Exchange (Stock Code: 720). Furthermore, Mr. Huang was the chairman of the board of directors of Alaunos Therapeutics Inc., whose shares are listed on NASDAQ Global Select Market, between 2021 and 2023. He was also a director of CASI PHARMACEUTICALS, INC., whose shares are listed on NASDAQ, between 2013 and 2023 and the chairman of the board of Windtree Therapeutics Inc., a company whose shares are listed on NASDAQ between 2019 and 2023.공시 • Mar 27Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 22, 2024Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 22, 2024. Agenda: To consider and approve the final dividend in respect of the year ended 31 December 2023 of HK1.0 cent per share in an aggregate amount of HK$5,888,000; and to consider other matters.공시 • Mar 26Lee's Pharmaceutical Holdings Limited Proposes Ordinary Final Dividend for the Year Ended 31 December 2023, Payable on 17 June 2024Lee's Pharmaceutical Holdings Limited proposed ordinary final dividend of HKD 0.01 per share for the year ended 31 December 2023. Date of shareholders' approval is 22 May 2024. Ex-dividend date is 28 May 2024. Record date is 31 May 2024. Payment date is 17 June 2024.공시 • Mar 15Lee's Pharmaceutical Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024Lee's Pharmaceutical Holdings Limited announced that they will report fiscal year 2023 results on Mar 26, 2024공시 • Aug 31Lee's Pharmaceutical Holdings Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, Payable on 04 October 2023Lee's Pharmaceutical Holdings Limited announced interim dividend of HKD 0.008 per share for the six months ended June 30, 2023. Ex-dividend date is 12 September 2023. Record date is 15 September 2023. Payment date is 04 October 2023.공시 • Aug 22+ 1 more updateLee's Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2023Lee's Pharmaceutical Holdings Limited provided earnings guidance for the six months ended 30 June 2023. For the period, the Group is expected to record an unaudited net profit attributable to the Shareholders of between HKD 12 million and HKD 17 million for the six months ended 30 June 2023 as compared with approximately HKD 28 million recorded for the six months ended 30 June 2022.공시 • Aug 19Lee's Pharmaceutical Holdings Limited to Report First Half, 2023 Results on Aug 30, 2023Lee's Pharmaceutical Holdings Limited announced that they will report first half, 2023 results on Aug 30, 2023공시 • May 18Lee's Pharmaceutical Holdings Limited Appoints Cheang Yee Wah, Eva as Independent Non-Executive DirectorLee's Pharmaceutical Holdings Limited approved to appoint Ms. Cheang Yee Wah, Eva as the independent non-executive director of the Company, at the AGM held on 17 May 2023.공시 • Jan 20Lee's Pharmaceutical Holdings Limited Announces Inclusion of Treprostinil Injection, Teglutik and Trittico in the National Reimbursement Drug ListLee's Pharmaceutical Holdings Limited announce that the Group's commercialised products, namely Treprostinil Injection, Teglutik® and Trittico® have been included for the first time into the updated National Reimbursement Drug List (the "NRDL") issued by the China National Healthcare Security Administration on 18 January 2023 and will be officially implemented from 1 March 2023. Together with the other 6 products in the list, a total of 9 products of the Group have been included in the updated NRDL. Among 111 products included for the first time in this updated NRDL, 7 of which are from rare disease area and the Group's Treprostinil Injecton and Teglutik® have taken up 2 places thereof. Together with Trittico®, the Group firmly believed that the newly inclusion of these specialty drugs into the updated NRDL will help the Group to further enhance the affordabilityand accessibility thereof among patients in rare disease and mental health areas.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: LPCU.F 의 배당금 지급은 지난 10 년 동안 휘발성이었습니다.배당금 증가: LPCU.F 의 배당금 지급액은 지난 10 년 동안 감소했습니다.배당 수익률 vs 시장Lee's Pharmaceutical Holdings 배당 수익률 vs 시장LPCU.F의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (LPCU.F)3.2%시장 하위 25% (US)1.4%시장 상위 25% (US)4.3%업계 평균 (Pharmaceuticals)2.1%분석가 예측 (LPCU.F) (최대 3년)3.2%주목할만한 배당금: LPCU.F 의 배당금( 3.18% )은 US 시장에서 배당금 지급자의 하위 25%( 1.39% )보다 높습니다.고배당: LPCU.F 의 배당금( 3.18% )은 US 시장에서 배당금 지급자의 상위 25%( 4.29% )와 비교해 낮습니다.주주 대상 이익 배당수익 보장: 합리적으로 낮은 지불 비율 ( 28.3% )로 LPCU.F 의 배당금 지급은 수익으로 충분히 충당됩니다.주주 현금 배당현금 흐름 범위: 현금 지급 비율 ( 17.4% )이 낮기 때문에 LPCU.F 의 배당금 지급은 현금 흐름으로 잘 충당됩니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/02/17 00:49종가2025/11/20 00:00수익2025/06/30연간 수익2024/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Lee's Pharmaceutical Holdings Limited는 6명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Chu WangCitigroup IncJun Zhou LiEverbright Securities Co. Ltd.Yue-Kwong LuiJefferies LLC3명의 분석가 더 보기
공시 • Mar 26Lee's Pharmaceutical Holdings Limited Proposes Ordinary Final Dividend for the Year Ended 31 December 2023, Payable on 17 June 2024Lee's Pharmaceutical Holdings Limited proposed ordinary final dividend of HKD 0.01 per share for the year ended 31 December 2023. Date of shareholders' approval is 22 May 2024. Ex-dividend date is 28 May 2024. Record date is 31 May 2024. Payment date is 17 June 2024.
공시 • Aug 31Lee's Pharmaceutical Holdings Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, Payable on 04 October 2023Lee's Pharmaceutical Holdings Limited announced interim dividend of HKD 0.008 per share for the six months ended June 30, 2023. Ex-dividend date is 12 September 2023. Record date is 15 September 2023. Payment date is 04 October 2023.
공시 • Mar 30Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 21, 2026Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 21, 2026.
공시 • Mar 17Lee's Pharmaceutical Holdings Limited to Report Fiscal Year 2025 Results on Mar 30, 2026Lee's Pharmaceutical Holdings Limited announced that they will report fiscal year 2025 results on Mar 30, 2026
공시 • Dec 10Lee's Pharmaceutical Holdings Limited (SEHK:950) signed asset purchase agreement to acquire Assets relating to Alexza Business of Alexza Pharmaceuticals, Inc., for $15 million.Lee's Pharmaceutical Holdings Limited (SEHK:950) signed asset purchase agreement to acquire Assets relating to Alexza Business of Alexza Pharmaceuticals, Inc., for $15 million on December 8, 2025. A cash consideration of $10 million will be paid by Lee's Pharmaceutical Holdings Limited. Lee's Pharmaceutical Holdings Limited will pay an earnout/contingent payment of $5 million cash which will be paid on June 1, 2026.. As part of consideration, $15 million is paid towards assets of Assets relating to Alexza Business of Alexza Pharmaceuticals, Inc.,. Assets relating to Alexza Business of Alexza Pharmaceuticals, Inc., reported total common equity of $58.67 million as on December 31, 2024. The expected completion of the transaction is December 8, 2025 to January 21, 2026.
공시 • Aug 15Lee's Pharmaceutical Holdings Limited to Report First Half, 2025 Results on Aug 26, 2025Lee's Pharmaceutical Holdings Limited announced that they will report first half, 2025 results on Aug 26, 2025
공시 • Mar 27Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 22, 2025Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 22, 2025.
공시 • Mar 12Lee's Pharmaceutical Holdings Limited to Report Fiscal Year 2024 Results on Mar 27, 2025Lee's Pharmaceutical Holdings Limited announced that they will report fiscal year 2024 results on Mar 27, 2025
공시 • Aug 16Lee's Pharmaceutical Holdings Limited to Report First Half, 2024 Results on Aug 28, 2024Lee's Pharmaceutical Holdings Limited announced that they will report first half, 2024 results on Aug 28, 2024
공시 • Aug 02Lee's Pharmaceutical Holdings Limited Announces the First Patient Has Been Enrolled in A Phase I Clinical Trial to Receive Au409 At Queen Mary Hospital, Hong KongLee's Pharmaceutical Holdings Limited announced that on 15 July 2024, the first patient has been enrolled in a Phase I clinical trial to receive AU409 at Queen Mary Hospital, Hong Kong. This trial focuses on patients with advanced hepatocellular carcinoma who have previously failed standard first-line treatment. AU409 is a novel drug discovered and owned by Auransa Inc. ("A Phase I, Single-arm, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of AU409 Capsule in Advanced Hepatocellular Carcinoma Patients who failed Standard Treatment" is led by Principal Investigator Dr. Chi Leung Chiang, MD. The primary objectives are to determine the maximum tolerated dose and recommended Phase II dose, as well as to characterise the safety and tolerability of AU409. Secondary objectives include assessing the pharmacokinetics and preliminary anti-tumor activity of AU409. AU409 is a novel drug discovered and owned by Auransa Inc. ("Auransa"), and is manufactured by Zhaoke Pharmaceutical (Guangzhou) Limited, a wholly owned subsidiary of the Group, in compliance with the Good Manufacturing Practice regulations set by the U.S. Food and Drug Administration. This Phase I clinical trial marks the first-in-human study in Asia and is expected to conclude by the second quarter of 2025. The results of this study will be used for China's new drug registration purpose.
공시 • Jul 02Lee's Pharmaceutical Holdings Limited Appoints Huang Zuie Chin as A Non-Executive DirectorThe board of directors of Lee's Pharmaceutical Holdings Limited announced that after considering the recommendation of the nomination committee of the Company, the Board has appointed Mr. Huang Zuie Chin as a non-executive Director with effect from 2 July 2024. Mr. Huang, aged 59, has over 35 years' experience in the life science and investment industry together with 20 years' experience in the pharmaceutical and biotech industry holding senior roles in business development, sales, marketing and research and development. In 2011, he joined Kleiner Perkins Caufield & Byers China as a managing partner and focuses on the firm's life science practice. He is also the founding managing partner of Panacea Healthcare Venture Capital, including Panacea Venture Healthcare Fund I, L.P., Panacea Venture Healthcare Fund II, L.P. and Panacea Opportunity Fund I, L.P., which are venture capitals focusing on investments in innovative and transformative early and growth stage healthcare and life sciences companies worldwide. Mr. Huang received a Master of Business Administration (MBA) from the Stanford Graduate School of Business and a Bachelor of Science degree in chemical engineering from the University of California, Berkeley. He is a non-executive director of Kindstar Globalgene Technology Inc., whose shares are listed on The Stock Exchange of Hong Kong Limited (the "Stock Exchange") (Stock Code: 9960) since 2012, and a director of Connect Biopharma Holdings Limited, a company whose shares are listed on Nasdaq Global Market since 2024. Between 2020 and 2023, he was an executive director of Auto Italia Holdings Limited, whose shares are listed on the Stock Exchange (Stock Code: 720). Furthermore, Mr. Huang was the chairman of the board of directors of Alaunos Therapeutics Inc., whose shares are listed on NASDAQ Global Select Market, between 2021 and 2023. He was also a director of CASI PHARMACEUTICALS, INC., whose shares are listed on NASDAQ, between 2013 and 2023 and the chairman of the board of Windtree Therapeutics Inc., a company whose shares are listed on NASDAQ between 2019 and 2023.
공시 • Mar 27Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 22, 2024Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 22, 2024. Agenda: To consider and approve the final dividend in respect of the year ended 31 December 2023 of HK1.0 cent per share in an aggregate amount of HK$5,888,000; and to consider other matters.
공시 • Mar 26Lee's Pharmaceutical Holdings Limited Proposes Ordinary Final Dividend for the Year Ended 31 December 2023, Payable on 17 June 2024Lee's Pharmaceutical Holdings Limited proposed ordinary final dividend of HKD 0.01 per share for the year ended 31 December 2023. Date of shareholders' approval is 22 May 2024. Ex-dividend date is 28 May 2024. Record date is 31 May 2024. Payment date is 17 June 2024.
공시 • Mar 15Lee's Pharmaceutical Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024Lee's Pharmaceutical Holdings Limited announced that they will report fiscal year 2023 results on Mar 26, 2024
공시 • Aug 31Lee's Pharmaceutical Holdings Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, Payable on 04 October 2023Lee's Pharmaceutical Holdings Limited announced interim dividend of HKD 0.008 per share for the six months ended June 30, 2023. Ex-dividend date is 12 September 2023. Record date is 15 September 2023. Payment date is 04 October 2023.
공시 • Aug 22+ 1 more updateLee's Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2023Lee's Pharmaceutical Holdings Limited provided earnings guidance for the six months ended 30 June 2023. For the period, the Group is expected to record an unaudited net profit attributable to the Shareholders of between HKD 12 million and HKD 17 million for the six months ended 30 June 2023 as compared with approximately HKD 28 million recorded for the six months ended 30 June 2022.
공시 • Aug 19Lee's Pharmaceutical Holdings Limited to Report First Half, 2023 Results on Aug 30, 2023Lee's Pharmaceutical Holdings Limited announced that they will report first half, 2023 results on Aug 30, 2023
공시 • May 18Lee's Pharmaceutical Holdings Limited Appoints Cheang Yee Wah, Eva as Independent Non-Executive DirectorLee's Pharmaceutical Holdings Limited approved to appoint Ms. Cheang Yee Wah, Eva as the independent non-executive director of the Company, at the AGM held on 17 May 2023.
공시 • Jan 20Lee's Pharmaceutical Holdings Limited Announces Inclusion of Treprostinil Injection, Teglutik and Trittico in the National Reimbursement Drug ListLee's Pharmaceutical Holdings Limited announce that the Group's commercialised products, namely Treprostinil Injection, Teglutik® and Trittico® have been included for the first time into the updated National Reimbursement Drug List (the "NRDL") issued by the China National Healthcare Security Administration on 18 January 2023 and will be officially implemented from 1 March 2023. Together with the other 6 products in the list, a total of 9 products of the Group have been included in the updated NRDL. Among 111 products included for the first time in this updated NRDL, 7 of which are from rare disease area and the Group's Treprostinil Injecton and Teglutik® have taken up 2 places thereof. Together with Trittico®, the Group firmly believed that the newly inclusion of these specialty drugs into the updated NRDL will help the Group to further enhance the affordabilityand accessibility thereof among patients in rare disease and mental health areas.